Skip to main content

Advertisement

Table 3 Descriptive characteristics and clinical evaluation results of participants with clinical Chronic Beryllium Disease at follow-up

From: Long-term follow-up of beryllium sensitized workers from a single employer

Parameter Pt.1 Pt.2 Pt. 3 Pt.4 Pt 5 Pt 6 Pt.7 Pt.8
Baseline diagnosis CBD CBD CBD CBD CBD CBD CBD BeS
Baseline to current evaluation, in yrs. 12 5 12 4 1 9 11 7
Yrs. since first worked at site to initial evaluation 4 10 23 1 26 22 8 18
Yrs. of beryllium exposure 15 12 29 2 27 36 10 25
Yrs. since last worked at site 6 3 6 3 0 9 10 0
Smoking Status Never smoker Never smoker Ex smoker Ex smoker Ex smoker Ex smoker Ex smoker Current smoker
No. of pack years 0 0 9 20 11 71 8 21.5
Steroid Use No Yes (Inhalational) No Yes (Inhalational) No Yes (Inhalational) Yes (oral) No
BeLPT result (Lab 1/Lab 2) +/+ +/- +/- +/+ +/+ -/- +/- +/+
Pulmonary Function tests (% predicted)
FEV1         
Initial 73 87 81 85 65 95 72 87
Final 62 93 79 89 63 85 70 71
FVC         
Initial 80 78 82 97 71 121 83 89
Final 62 87 82 96 69 89 79 68
FEV1/FVC         
Initial 92 111 100 88 92 78 87 97
Final 99 107 98 92 89 94 88 106
TLC         
Initial 88 78 97 107 95 96 95 88
Final 80 58 88 91 87 89 N/A 79
DLCO         
Initial 108 95 124 98 N/A 97 131 116
Final 49 69 56 64 53 62 N/A 82
X-ray Changes or CBD Bilateral hilar adenopathy and diffuse small opacities None None None None Borderline enlargement of lymph nodes None None
Basis for Clinical CBD X-ray, Low DLCO, Low FVC Low TLC, Low DLCO Low
DLCO
Low DLCO Low FVC, Low DLCO X-ray, Low DLCO On oral steroids for presumed clinical CBD Low FVC, Low TLC